Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Lung Cancer

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 67 articles: HTML format Text format

Single Articles

March 2019
1. ANTONIA SJ
   Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Reply.
   N Engl J Med. 2019;380:990.
   PubMed     Text format    
   
   
   
2. KIM YH
   Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
   N Engl J Med. 2019;380:989-990.
   PubMed     Text format    
   
   
   February 2019
3. HORN L, Liu SV
   Atezolizumab plus Chemotherapy in Small-Cell Lung Cancer. Reply.
   N Engl J Med. 2019;380:889-890.
   PubMed     Text format    
   
   
   
4. DIKER O
   Atezolizumab plus Chemotherapy in Small-Cell Lung Cancer.
   N Engl J Med. 2019;380:889.
   PubMed     Text format    
   
   
   
5. WEISS GJ, Addeo A
   Atezolizumab plus Chemotherapy in Small-Cell Lung Cancer.
   N Engl J Med. 2019;380:888-889.
   PubMed     Text format    
   
   
   December 2018
6. AMPOLLINI L, Rusca M
   Erythroderma and a Pulmonary Nodule.
   N Engl J Med. 2018;379:e41.
   PubMed     Text format    
   
   
   
7. ANTONIA SJ, Villegas A, Daniel D, Vicente D, et al
   Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
   N Engl J Med. 2018;379:2342-2350.
   PubMed     Text format     Abstract available
   
   
   November 2018
8. PATIL T, Pacheco JM
   Miliary Metastases in Non-Small-Cell Lung Cancer.
   N Engl J Med. 2018;379:1945.
   PubMed     Text format    
   
   
   
9. MANLEY C, Olszanski A
   Melanoma in the Bronchus.
   N Engl J Med. 2018;379:e36.
   PubMed     Text format    
   
   
   October 2018
10. NEILAN TG, Price MC, Sanborn DY, Gainor JF, et al
    Case 33-2018: A 57-Year-Old Man with Confusion, Fever, Malaise, and Weight Loss.
    N Engl J Med. 2018;379:1658-1669.
    PubMed     Text format    
    
    
    
11. KWATRA SG, Stander S, Kang H
    PD-1 Blockade-Induced Pruritus Treated with a Mu-Opioid Receptor Antagonist.
    N Engl J Med. 2018;379:1578-1579.
    PubMed     Text format    
    
    
    September 2018
12. CAMIDGE DR, Kim HR, Ahn MJ, Yang JC, et al
    Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
    N Engl J Med. 2018 Sep 25. doi: 10.1056/NEJMoa1810171.
    PubMed     Text format     Abstract available
    
    
    
13. HORN L, Mansfield AS, Szczesna A, Havel L, et al
    First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
    N Engl J Med. 2018 Sep 25. doi: 10.1056/NEJMoa1809064.
    PubMed     Text format     Abstract available
    
    
    
14. PAZ-ARES L, Luft A, Vicente D, Tafreshi A, et al
    Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
    N Engl J Med. 2018 Sep 25. doi: 10.1056/NEJMoa1810865.
    PubMed     Text format     Abstract available
    
    
    
15. ASHRAF N
    Atezolizumab Treatment of Nonsquamous NSCLC.
    N Engl J Med. 2018;379:1187-8.
    PubMed     Text format    
    
    
    
16. MOUNTZIOS G, Calles A, Addeo A
    Atezolizumab Treatment of Nonsquamous NSCLC.
    N Engl J Med. 2018;379:1187.
    PubMed     Text format    
    
    
    
17. RECK M, Jotte RM, Socinski MA
    Atezolizumab Treatment of Nonsquamous NSCLC.
    N Engl J Med. 2018;379:1188.
    PubMed     Text format    
    
    
    
18. DIKER O
    Pembrolizumab plus Chemotherapy in Lung Cancer.
    N Engl J Med. 2018;379:e18.
    PubMed     Text format    
    
    
    
19. SUN R, Rich MW, Wei LJ
    Pembrolizumab plus Chemotherapy in Lung Cancer.
    N Engl J Med. 2018;379:e18.
    PubMed     Text format    
    
    
    
20. GIL-SIERRA MD, Fenix-Caballero S, Alegre-del Rey E
    Pembrolizumab plus Chemotherapy in Lung Cancer.
    N Engl J Med. 2018;379:e19.
    PubMed     Text format    
    
    
    
21. VANDERLAAN PA, Rangachari D, Costa DB
    Lung Cancer with a High Tumor Mutational Burden.
    N Engl J Med. 2018;379:1093.
    PubMed     Text format    
    
    
    
22. 
    Pembrolizumab plus Chemotherapy in Lung Cancer.
    N Engl J Med. 2018;379:e18.
    PubMed     Text format    
    
    
    
23. 
    Lung Cancer with a High Tumor Mutational Burden.
    N Engl J Med. 2018;379:1093-1094.
    PubMed     Text format    
    
    
    
24. CONTI L, Gatt S
    Squamous-Cell Carcinoma of the Lung.
    N Engl J Med. 2018;379:e17.
    PubMed     Text format    
    
    
    
25. AL-KINDI S, Al-Juhaishi T, Yaqoob Z
    Incidence of Lung Cancer among Young Women.
    N Engl J Med. 2018;379:988-9.
    PubMed     Text format    
    
    
    
26. BERLIN I
    Incidence of Lung Cancer among Young Women.
    N Engl J Med. 2018;379:988.
    PubMed     Text format    
    
    
    
27. FUNATOGAWA I
    Incidence of Lung Cancer among Young Women.
    N Engl J Med. 2018;379:988.
    PubMed     Text format    
    
    
    
28. 
    Incidence of Lung Cancer among Young Women.
    N Engl J Med. 2018;379:988-991.
    PubMed     Text format    
    
    
    August 2018
29. 
    Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
    N Engl J Med. 2018;379:e14.
    PubMed     Text format    
    
    
    
30. LOMMATZSCH M, Bratke K, Stoll P
    Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
    N Engl J Med. 2018;379:e14.
    PubMed     Text format    
    
    
    
31. YANG X, Yin R, Xu L
    Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
    N Engl J Med. 2018;379:e14.
    PubMed     Text format    
    
    
    June 2018
32. SOCINSKI MA, Jotte RM, Cappuzzo F, Orlandi F, et al
    Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
    N Engl J Med. 2018;378:2288-2301.
    PubMed     Text format     Abstract available
    
    
    
33. DE KOCK L, Fahiminiya S, Fiset PO, Astigarraga I, et al
    Infantile Pulmonary Teratoid Tumor.
    N Engl J Med. 2018;378:2238-2240.
    PubMed     Text format    
    
    
    
34. SCLAFANI A, VanderLaan P
    Lymphangioleiomyomatosis.
    N Engl J Med. 2018;378:2224.
    PubMed     Text format    
    
    
    May 2018
35. SCHILLER JH
    A New Standard of Care for Advanced Lung Cancer.
    N Engl J Med. 2018;378:2135-2137.
    PubMed     Text format    
    
    
    
36. JEMAL A, Miller KD, Ma J, Siegel RL, et al
    Higher Lung Cancer Incidence in Young Women Than Young Men in the United States.
    N Engl J Med. 2018;378:1999-2009.
    PubMed     Text format     Abstract available
    
    
    
37. ELMORE SNC
    p53 and Me.
    N Engl J Med. 2018;378:1962-1963.
    PubMed     Text format    
    
    
    April 2018
38. GANDHI L, Rodriguez-Abreu D, Gadgeel S, Esteban E, et al
    Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
    N Engl J Med. 2018 Apr 16. doi: 10.1056/NEJMoa1801005.
    PubMed     Text format     Abstract available
    
    
    
39. FORDE PM, Chaft JE, Smith KN, Anagnostou V, et al
    Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
    N Engl J Med. 2018 Apr 16. doi: 10.1056/NEJMoa1716078.
    PubMed     Text format     Abstract available
    
    
    
40. HELLMANN MD, Ciuleanu TE, Pluzanski A, Lee JS, et al
    Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
    N Engl J Med. 2018 Apr 16. doi: 10.1056/NEJMoa1801946.
    PubMed     Text format     Abstract available
    
    
    
41. MAMDANI H, Grethlein SJ
    Pulmonary Metastases from Chondroblastic Osteosarcoma.
    N Engl J Med. 2018;378:1429.
    PubMed     Text format    
    
    
    March 2018
42. CHOI JY, Choi YJ, Shin SW
    Osimertinib in EGFR Mutation-Positive Advanced NSCLC.
    N Engl J Med. 2018;378:1262.
    PubMed     Text format    
    
    
    
43. ROCA E, Amoroso V, Berruti A
    Osimertinib in EGFR Mutation-Positive Advanced NSCLC.
    N Engl J Med. 2018;378:1261-2.
    PubMed     Text format    
    
    
    
44. WARD MC, Prabhu RS, Burri SH
    Osimertinib in EGFR Mutation-Positive Advanced NSCLC.
    N Engl J Med. 2018;378:1261.
    PubMed     Text format    
    
    
    
45. 
    Osimertinib in EGFR Mutation-Positive Advanced NSCLC.
    N Engl J Med. 2018;378:1261-1263.
    PubMed     Text format    
    
    
    
46. WEINSTOCK M, Vaidya A, El-Chemaly S, Godleski J, et al
    The Verge of Collapse.
    N Engl J Med. 2018;378:e18.
    PubMed     Text format    
    
    
    
47. 
    Durvalumab in Stage III Non-Small-Cell Lung Cancer.
    N Engl J Med. 2018;378:868-870.
    PubMed     Text format    
    
    
    
48. SANTONI M, Battelli N, Buti S
    Durvalumab in Stage III Non-Small-Cell Lung Cancer.
    N Engl J Med. 2018;378:869.
    PubMed     Text format    
    
    
    
49. COPUR MD, Gauchan D, Ramaekers R
    Durvalumab in Stage III Non-Small-Cell Lung Cancer.
    N Engl J Med. 2018;378:868.
    PubMed     Text format    
    
    
    January 2018
50. POPAT S
    Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer.
    N Engl J Med. 2018;378:192-193.
    PubMed     Text format    
    
    
    November 2017
51. SORIA JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, et al
    Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017 Nov 18. doi: 10.1056/NEJMoa1713137.
    PubMed     Text format     Abstract available
    
    
    
52. SOHAL SS, Walers EH
    Advanced Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;377:1998-9.
    PubMed     Text format    
    
    
    
53. REN C, Han C, Wang D
    Advanced Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;377:1998.
    PubMed     Text format    
    
    
    
54. KWON HW, Ham SY, Shin SW
    Advanced Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;377:1997-8.
    PubMed     Text format    
    
    
    
55. RIZVI NA, Peters S
    Immunotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;377:1986-1988.
    PubMed     Text format    
    
    
    
56. 
    Advanced Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;377:1999.
    PubMed     Text format    
    
    
    September 2017
57. ANTONIA SJ, Villegas A, Daniel D, Vicente D, et al
    Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017 Sep 8. doi: 10.1056/NEJMoa1709937.
    PubMed     Text format     Abstract available
    
    
    August 2017
58. RECK M, Rabe KF
    Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;377:849-861.
    PubMed     Text format    
    
    
    June 2017
59. CARBONE DP, Reck M, Paz-Ares L, Creelan B, et al
    First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017;376:2415-2426.
    PubMed     Text format     Abstract available
    
    
    
60. PETERS S, Camidge DR, Shaw AT, Gadgeel S, et al
    Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017 Jun 6. doi: 10.1056/NEJMoa1704795.
    PubMed     Text format     Abstract available
    
    
    
61. ROBLES AI, Zenklusen JC
    Seeing the Forest through the Phylogenetic Tree.
    N Engl J Med. 2017;376:2190-2191.
    PubMed     Text format    
    
    
    May 2017
62. NISHINO M, Hatabu H
    Osimertinib in EGFR T790M-Positive Lung Cancer.
    N Engl J Med. 2017;376:1992-3.
    PubMed     Text format    
    
    
    
63. YIN Y, Li J
    Osimertinib in EGFR T790M-Positive Lung Cancer.
    N Engl J Med. 2017;376:1993.
    PubMed     Text format    
    
    
    
64. 
    Osimertinib in EGFR T790M-Positive Lung Cancer.
    N Engl J Med. 2017;376:1993-4.
    PubMed     Text format    
    
    
    
65. ZHANG BM, Aleshin A, Lin CY, Ford J, et al
    IDH2 Mutation in a Patient with Metastatic Colon Cancer.
    N Engl J Med. 2017;376:1991-2.
    PubMed     Text format    
    
    
    April 2017
66. JAMAL-HANJANI M, Wilson GA, McGranahan N, Birkbak NJ, et al
    Tracking the Evolution of Non-Small-Cell Lung Cancer.
    N Engl J Med. 2017 Apr 26. doi: 10.1056/NEJMoa1616288.
    PubMed     Text format     Abstract available
    
    
    March 2017
67. DEFILIPPIS EM, Vaidya A, Ramani S, French C, et al
    Under Pressure.
    N Engl J Med. 2017;376:e23.
    PubMed     Text format    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: